Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma
OSLO, Norway, June 6, 2025 /PRNewswire/ — Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal …